Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29619416 | 0.95 | GRIN2B (0.40) | GRIN2BGRIN2CJAK3USP2SMN1; SMN2 | |
| SCHEMBL27973224 | 0.83 | GRIN2B (0.40) | GRIN2BGRIN2CJAK3USP2SMN1; SMN2 | |
| SCHEMBL2246036 | 0.81 | GRIN2B (0.43) | GRIN2BGRIN2CJAK3USP2SMN1; SMN2 | |
| SCHEMBL8528362 | 0.80 | GRIN2B (0.45) | GRIN2BGRIN2CJAK3USP2SMN1; SMN2 | |
| SCHEMBL29214285 | 0.79 | JAK3 (0.40) | GRIN2BGRIN2CJAK3USP2SMN1; SMN2 | |
| SCHEMBL192363 | 0.79 | GRIN2B (0.41) | GRIN2BGRIN2CJAK3USP2SMN1; SMN2 | |
| SCHEMBL2429525 | 0.79 | GRIN2B (0.41) | GRIN2BGRIN2CJAK3USP2SMN1; SMN2 | |
| SCHEMBL2774828 | 0.79 | GRIN2B (0.41) | GRIN2BGRIN2CJAK3USP2SMN1; SMN2 | |
| SCHEMBL1268184 | 0.79 | GRIN2B (0.41) | GRIN2BGRIN2CJAK3USP2SMN1; SMN2 | |
| SCHEMBL387543 | 0.79 | GRIN2B (0.41) | GRIN2BGRIN2CJAK3USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071223-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4646213-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE | Arrowhead Pharmaceuticals, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| WO-2024148329-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE | Arrowhead Pharmaceuticals, Inc. (US) | 2024-07-11 | — | — | WO | disclosed |
| CN-117658886-A | Hydrazide peptide deformylase inhibitor and preparation method and application thereof | 河南师范大学 | 2024-03-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071223-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE | FABP4, PLIN1, PLIN3 | GRIN2B 4728/4885GRIN2C 4804/4885JAK3 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.